All news

Could Acadia Pharmaceuticals (ACAD) Be 30% Undervalued Following Mixed Q3 Results?

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Acadia Pharmaceuticals (ACAD) recently reported mixed Q3 2026 results with revenue of US$342.29 million and net income of US$53.52 million. Despite recent share price weakness, the company is considered 30% undervalued with a fair value of $30.53, supported by disciplined capital allocation and a promising pipeline. Investors are advised to consider both growth prospects and risks before making investment decisions.

Read original source

ACAD company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.